Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.

Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O (2015)
BMC Public Health 15: 533.

Download
OA
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Volltext vorhanden für diesen Nachweis
Autor
; ; ; ; ;
Abstract / Bemerkung
BACKGROUND: A systematic review was conducted to assess the cost-effectiveness of routine varicella and herpes zoster (HZ) vaccination in high-income countries estimated by modelling studies.; METHODS: A PubMed search was performed to identify relevant studies published before October 2013. Studies were included in the review if they (i) evaluated the cost-effectiveness of routine childhood or adolescent varicella vaccination and/or HZ vaccination targeting the elderly, and if they (ii) reported results for high-income countries.; RESULTS: A total of 38 model-based studies were identified that fulfilled the inclusion criteria. Routine childhood or adolescent varicella vaccination was cost-effective or cost-saving from a payer perspective and always cost-saving from a societal perspective when ignoring its potential impact on HZ incidence due to reduced or absent exogenous boosting. The inclusion of the potential impact of childhood varicella vaccination on HZ led to net quality-adjusted life-year (QALY) losses or incremental cost-effectiveness ratios exceeding commonly accepted thresholds. Additional HZ vaccination could partially mitigate this effect. Studies focusing only on the evaluation of HZ vaccination reported a wide range of results depending on the selected target age-group and the vaccine price, but most found HZ vaccination to be a cost-effective or marginally cost-effective intervention. Cost-effectiveness of HZ vaccination was strongly dependent on the age at vaccination, the price of the vaccine, the assumed duration of protection and the applied cost per QALY threshold.; CONCLUSIONS: While HZ vaccination is mostly considered cost-effective, cost-effectiveness of varicella vaccination primarily depends on the in- or exclusion of exogenous boosting in the model. As a consequence, clarification on the role of exogenous boosting is crucial for decision-making regarding varicella vaccination.
Erscheinungsjahr
Zeitschriftentitel
BMC Public Health
Band
15
Art.-Nr.
533
ISSN
Finanzierungs-Informationen
Article Processing Charge funded by the Deutsche Forschungsgemeinschaft and the Open Access Publication Fund of Bielefeld University.
PUB-ID

Zitieren

Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health. 2015;15: 533.
Damm, O., Ultsch, B., Horn, J., Mikolajczyk, R. T., Greiner, W., & Wichmann, O. (2015). Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health, 15, 533. doi:10.1186/s12889-015-1861-8
Damm, O., Ultsch, B., Horn, J., Mikolajczyk, R. T., Greiner, W., and Wichmann, O. (2015). Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health 15:533.
Damm, O., et al., 2015. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health, 15: 533.
O. Damm, et al., “Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.”, BMC Public Health, vol. 15, 2015, : 533.
Damm, O., Ultsch, B., Horn, J., Mikolajczyk, R.T., Greiner, W., Wichmann, O.: Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health. 15, : 533 (2015).
Damm, Oliver, Ultsch, Bernhard, Horn, Johannes, Mikolajczyk, Rafael T, Greiner, Wolfgang, and Wichmann, Ole. “Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.”. BMC Public Health 15 (2015): 533.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Copyright Statement:
This Item is protected by copyright and/or related rights. [...]
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2016-02-26T06:54:36Z

15 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Varicella in Poland: economic burden in children 1-12 years of age in Poland, 2010-2015.
Wysocki J, Malecka I, Stryczynska-Kazubska J, Rampakakis E, Kuter B, Wolfson LJ., BMC Public Health 18(1), 2018
PMID: 29587714
Differential uptake of herpes zoster vaccination associated with socioeconomic status: A population-based study in Stockholm County, Sweden.
Fogelberg S, Lamb F, Grönlund O, Eriksson I, Sundström K, Clements M, Arnheim-Dahlström L., Pharmacoepidemiol Drug Saf 27(11), 2018
PMID: 30221421
Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR, Ademi Z, Lu X, Szucs TD, Schwenkglenks M., Hum Vaccin Immunother 13(7), 2017
PMID: 28481678
Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
Meyers JL, Madhwani S, Rausch D, Candrilli SD, Krishnarajah G, Yan S., Hum Vaccin Immunother 13(8), 2017
PMID: 28605285
Varicella vaccination - the global experience.
Wutzler P, Bonanni P, Burgess M, Gershon A, Sáfadi MA, Casabona G., Expert Rev Vaccines 16(8), 2017
PMID: 28644696
Post-herpetic neuralgia - a review of current management and future directions.
Schutzer-Weissmann J, Farquhar-Smith P., Expert Opin Pharmacother 18(16), 2017
PMID: 29025327
Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, Peterson J, Vastiau I, Oostvogels L., J Infect Dis 216(11), 2017
PMID: 29029122
Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections.
Sauerbrei A., Eur J Clin Microbiol Infect Dis 35(5), 2016
PMID: 26873382
Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.
Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O., Pharmacoeconomics 34(3), 2016
PMID: 26477039
The cost of vaccination throughout life: A western European overview.
Ethgen O, Cornier M, Chriv E, Baron-Papillon F., Hum Vaccin Immunother 12(8), 2016
PMID: 27050111
How much money is spent on vaccines across Western European countries?
Ethgen O, Baron-Papillon F, Cornier M., Hum Vaccin Immunother 12(8), 2016
PMID: 27224429
Cost-effectiveness of a herpes zoster vaccination program among the French elderly people.
Belchior E, Lévy-Bruhl D, Le Strat Y, Herida M., Hum Vaccin Immunother 12(9), 2016
PMID: 27484158
The 'Dynamic' Marriage Between Varicella and Zoster.
de Boer PT, Wilschut JC, Postma MJ., EBioMedicine 2(10), 2015
PMID: 26629519

72 References

Daten bereitgestellt von Europe PubMed Central.

Epidemiology, outcome and control of varicella-zoster infection
Miller E, Marshall R, Vurdien J., 1993
Seroprevalence of varicella-zoster virus in the German population.
Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A., Vaccine 20(1-2), 2001
PMID: 11567755
Herpes zoster and postherpetic neuralgia in older adults.
Schmader K., Clin. Geriatr. Med. 23(3), 2007
PMID: 17631237
Postherpetic neuralgia.
Hope-Simpson RE., J R Coll Gen Pract 25(157), 1975
PMID: 1195231
Pain and its persistence in herpes zoster.
Dworkin RH, Portenoy RK., Pain 67(2-3), 1996
PMID: 8951917
Varicella vaccination in Europe - taking the practical approach.
Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou V, Rentier B, Rumke H, Sadzot-Delvaux C, Senterre J, Weil-Olivier C, Wutzler P., BMC Med 7(), 2009
PMID: 19476611
Consensus: varicella vaccination of healthy children--a challenge for Europe.
Rentier B, Gershon AA; European Working Group on Varicella., Pediatr. Infect. Dis. J. 23(5), 2004
PMID: 15131459
Impact of the routine varicella vaccination programme on varicella epidemiology in Germany
Siedler A, Arndt U., 2010
Is Europe ready to embrace a policy of universal varicella vaccination?
Ramet J, Weil-Olivier C, Sedlak W; Confederation of the European Specialists of Paediatrics (CESP)/European Academy of Paediatrics (EAP) CESP/EAP., Int. J. Clin. Pract. 59(11), 2005
PMID: 16236088
Varicella disease after introduction of varicella vaccine in the United States, 1995-2000.
Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, Maupin TJ, Goldman GS, Tabony LJ, Brodovicz KG, Jumaan AO, Wharton M., JAMA 287(5), 2002
PMID: 11829699

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Statement on the recommended use of herpes zoster vaccine
AUTHOR UNKNOWN, 2010

AUTHOR UNKNOWN, 0
THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS.
HOPE-SIMPSON RE., Proc. R. Soc. Med. 58(), 1965
PMID: 14267505
Herpes zoster and postherpetic neuralgia: past, present and future.
Bennett GJ, Watson CP., Pain Res Manag 14(4), 2009
PMID: 19714266
The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review.
Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF., J. Infect. Dis. 197 Suppl 2(), 2008
PMID: 18419401

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group, Altman D, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J, Clarke M, Cook D, D'Amico R, Deeks JJ, Devereaux PJ, Dickersin K, Egger M, Ernst E, Gotzsche PC, Grimshaw J, Guyatt G, Higgins J, Ioannidis JP, Kleijnen J, Lang T, Liberati A, Magrini N, McNamee D, Moja L, Moher D, Mulrow C, Napoli M, Oxman A, Pham B, Rennie D, Sampson M, Schulz KF, Shekelle PG, Tetzlaff J, Tovey D, Tugwell P., BMJ 339(), 2009
PMID: 19622551
Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M, Marra CA, Galanis E, Patrick DM., Pharmacoeconomics 27(12), 2009
PMID: 19908924
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group., N. Engl. J. Med. 352(22), 2005
PMID: 15930418
An economic analysis of the universal varicella vaccination program in the United States.
Zhou F, Ortega-Sanchez IR, Guris D, Shefer A, Lieu T, Seward JF., J. Infect. Dis. 197 Suppl 2(), 2008
PMID: 18419391
The cost-effectiveness of varicella vaccination in Canada.
Brisson M, Edmunds WJ., Vaccine 20(7-8), 2002
PMID: 11803072
Varicella vaccination in England and Wales: cost-utility analysis.
Brisson M, Edmunds WJ., Arch. Dis. Child. 88(10), 2003
PMID: 14500303
The cost-effectiveness of varicella vaccine programs for Australia.
Scuffham PA, Lowin AV, Burgess MA., Vaccine 18(5-6), 1999
PMID: 10519929
The cost-effectiveness of routine childhood varicella vaccination in Germany.
Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, Wutzler P., Vaccine 21(11-12), 2003
PMID: 12559807
Costs and benefits of routine varicella vaccination in German children
Beutels P, Clara R, Tormans G, van E, van P., 1996
Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P., Vaccine 30(3), 2011
PMID: 22120193
Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O., BMC Health Serv Res 13(), 2013
PMID: 24070414
Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ., Vaccine 31(9), 2013
PMID: 23306360
Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.
van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE., BMC Health Serv Res 10(), 2010
PMID: 20707884
Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Rothberg MB, Virapongse A, Smith KJ., Clin. Infect. Dis. 44(10), 2007
PMID: 17443464
Economic evaluations of varicella vaccination programmes: a review of the literature.
Thiry N, Beutels P, Van Damme P, Van Doorslaer E., Pharmacoeconomics 21(1), 2003
PMID: 12484801
Cost-effectiveness of varicella vaccination programs: an update of the literature.
Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ., Expert Rev Vaccines 7(6), 2008
PMID: 18665775
Economic evaluation of Varicella vaccination: results of a systematic review.
Unim B, Saulle R, Boccalini S, Taddei C, Ceccherini V, Boccia A, Bonanni P, La Torre G., Hum Vaccin Immunother 9(9), 2013
PMID: 23823940
A systematic review of the cost effectiveness of herpes zoster vaccination.
Szucs TD, Pfeil AM., Pharmacoeconomics 31(2), 2013
PMID: 23335045
Epidemiological features and economic evaluation of a potential chickenpox vaccination strategy in Slovak Republic.
Hudeckova H, Straka S, Rusnakova S., Cent. Eur. J. Public Health 8(4), 2000
PMID: 11125976
Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another.
Goeree R, Burke N, O'Reilly D, Manca A, Blackhouse G, Tarride JE., Curr Med Res Opin 23(4), 2007
PMID: 17407623
Economic evaluation of varicella vaccination in Swiss children and adolescents.
Banz K, Iseli A, Aebi C, Brunner M, Schmutz AM, Heininger U., Hum Vaccin 5(12), 2009
PMID: 19829048
Varicella vaccination in Italy : an economic evaluation of different scenarios.
Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B., Pharmacoeconomics 22(13), 2004
PMID: 15329030
The economic value of childhood varicella vaccination in France and Germany.
Coudeville L, Brunot A, Szucs TD, Dervaux B., Value Health 8(3), 2005
PMID: 15877593
A cost benefit analysis of routine varicella vaccination in Spain.
Diez Domingo J, Ridao M, Latour J, Ballester A, Morant A., Vaccine 17(11-12), 1999
PMID: 10195765
Instituting a routine varicella vaccination program in Canada: an economic evaluation.
Getsios D, Caro JJ, Caro G, De Wals P, Law BJ, Robert Y, Lance JM., Pediatr. Infect. Dis. J. 21(6), 2002
PMID: 12182379
Childhood vaccination against chickenpox: an analysis of benefits and costs.
Huse DM, Meissner HC, Lacey MJ, Oster G., J. Pediatr. 124(6), 1994
PMID: 8201469
Economic evaluation of varicella vaccination in Spain: results from a dynamic model.
Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B., Vaccine 24(47-48), 2006
PMID: 16860909
Cost-effectiveness of a routine varicella vaccination program for US children.
Lieu TA, Cochi SL, Black SB, Halloran ME, Shinefield HR, Holmes SJ, Wharton M, Washington AE., JAMA 271(5), 1994
PMID: 8283587
A benefit-cost analysis of a childhood varicella vaccination programme.
Preblud SR, Orenstein WA, Koplan JP, Bart KJ, Hinman AR., Postgrad Med J 61 Suppl 4(), 1985
PMID: 3939152
The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule.
Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R., Soc Sci Med 49(6), 1999
PMID: 10459888
An economic evaluation of varicella vaccination in Italian adolescents.
Thiry N, Beutels P, Tancredi F, Romano L, Zanetti A, Bonanni P, Gabutti G, Van Damme P., Vaccine 22(27-28), 2004
PMID: 15315834
Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.
Bresse X, Annemans L, Preaud E, Bloch K, Duru G, Gauthier A., Expert Rev Pharmacoecon Outcomes Res 13(3), 2013
PMID: 23537397
The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M, Pellissier JM, Camden S, Quach C, De Wals P., Hum Vaccin 4(3), 2008
PMID: 18382137
A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.
Moore L, Remy V, Martin M, Beillat M, McGuire A., Cost Eff Resour Alloc 8(), 2010
PMID: 20433704
Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.
Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X., Hum Vaccin 7(7), 2011
PMID: 21606685
Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.
van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ., Vaccine 27(9), 2009
PMID: 19135492

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 26041469
PubMed | Europe PMC

Suchen in

Google Scholar